Merck recently announced the opening of its first Microbiology Application and Training (MAT) Lab in Jigani, Bengaluru, offering facilities and technical expertise to support the Indian lifescience community on microbial quality control capability development, according to a company statement.
The statement said that the lab offers customisable solutions and services that help pharma and biopharma companies as well as regulatory to improve their processes from drug discovery, development to manufacturing.
With an investment of €200,000, the MAT Centre spans an area size of 1,100 sqft. The testing services offered in the lab include sterility testing, rapid bioburden testing, pyrogen testing, advance membrane filtration and other pharma QC microbiology applications. The MAT lab includes a vibrant space for certified training, application support, feasibilities studies and method development for pharma and biopharma industries, according to the statement.
Veena Panicker, Head, BioMonitoring, Merck Life Science, India, said in the statement, “According to IBEF, the Indian biotechnology industry was valued at $70.2 billion in 2020, and is expected to reach $150 billion by 2025. Merck’s MAT lab will be a space for pharma and biopharma companies to collaborate and enhance their capability in microbiology analysis.”